- The trend backdrop is active with a 16-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Volume is elevated versus the 13-week average, confirming attention.
- Activity pressure is constructive, supporting the smart-money activity read.
IART
NASDAQ
Week ended 18 Sep 2026
Weekly Investor Report
Integra LifeSciences Holdings · Healthcare · Medical Devices
Latest close
15.22 USD
-1.8%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 3.8% above the Trend Line and sits at 55.3% of its 52-week range. The latest completed week returned -1.8%, after a -9.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: earnings are due in 39d.
Setup score
41
out of 100
Latest Close
15.22 USD
18 Sep 2026
1W Return
-1.8%
latest completed week
4W Return
-9.1%
short-term follow-through
12W Return
-18.9%
quarterly tape
Trend Breadth
30.8%
16 of 52 weeks active
Volume Ratio
1.6x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.8%
Latest completed week; four-week move -9.1%.
Indicator stack
62/0
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Volatility
46/100 conviction; expected move 6.8%.
News sentiment
49/100
10 relevant articles in the latest sentiment read.
Event risk
39d
Next report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 3.8% above the Trend Line and sits at 55.3% of its 52-week range. The latest completed week returned -1.8%, after a -9.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
18 Sep
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7312-week average 0.85
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.73Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -9.1% over four weeks, -18.9% over 12 weeks, and 7.7% over one year. The current trend has remained active for 16 consecutive weeks.
Performance by holding period
Active trend streak16 weeks
Active weeks in one year16
Trend breadth30.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.65Latest activity-pressure read.
Pressure change-1805.3%Four-week change in activity pressure.
Leadership-0.28Latest relative-leadership reading.
RS change-102.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers.
Factor week 11 Sep 2026
Financial statements through 30 Jun 2026
Field coverage 88%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength81/100Blend of value, momentum, and quality. Underlying universe rank 20; rank 1 is best.
Value83/100Relative valuation strength. Underlying universe rank 18; rank 1 is best.
Quality67/100Profitability and accounting quality. Underlying universe rank 34; rank 1 is best.
Momentum33/100Medium-term price momentum. Underlying universe rank 68; rank 1 is best.
Growth25/100Revenue and earnings growth. Underlying universe rank 76; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework98/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.7x Market value relative to trailing revenue.
- EV / EBITDA
- 13.3x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 0.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 53.7% Gross profit retained from each unit of revenue.
- Operating margin
- 39.8% Operating profit retained from revenue.
- Free-cash-flow margin
- 0.5% Free cash flow generated from revenue.
- Return on invested capital
- 17.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 1.6% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -281.3% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.1% Net share repurchases relative to market value.
- Shareholder yield
- -0.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 8.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
IART shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 0.46, expected move of 6.8%, and Sharemaestro trend signal active.
Conviction46/100
Expected move6.8%
Put/call volume0.46
Insider activity13 / 4
13 acquisitions and 4 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment49/100
Weighted news tone is neutral across 10 relevant articles.
4 positive · 4 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings39dNext report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
Options expected move6.8%Nearest-chain priced movement where available.
52-week drawdown-25.7%Distance below the 52-week high.
13-week volatility6.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
27 Mar
24 Apr
22 May
19 Jun
17 Jul
14 Aug
18 Sep
Weeks higher18 of 268 weeks finished lower.
Best week+27.1%Week of 8 May.
Worst week-15.9%Week of 31 Jul.
Latest week-1.8%Week of 18 Sep.
Shape of recent returns
Strong gains9
Modest gains9
Flat weeks0
Modest losses4
Sharp losses4
Recent vol6.3%13-week weekly-return volatility.
Base vol8.3%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -6.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-2.8%
Trend breadth69.0%
Trend69.0%active weekly trend signals
MD68.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Medical Devices
4-week rank60 / 100
Group average-5.4%
Trend breadth45.0%
Trend45.0%active weekly trend signals
MD53.0%positive activity pressure
RS32.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape45/100
Trend, activity pressure, participation, and risk combine to a 45/100 tape read.
Indicator analysis78/100Latest 12-week confirmation: trend 12/12, activity pressure 8/12, relative leadership 11/12.
Activity pressure 0.73; No reversal markers Factors66/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 80; Small Cap Core rank 40 SVQF98/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 18.0 of 725 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options51/100IART shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 0.46, expected move of 6.8%, and Sharemaestro trend signal active.
Volatility · Volatility expansion watch · Expected move 6.8% Sentiment49/100Weighted news tone is neutral across 10 relevant articles.
Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks Insiders13 / 413 acquisitions and 4 disposals in the latest 180-day insider tape.
Earnings39dNext report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 18 Sep 2026 | 15.22 USD | -1.8% | 14.67 USD | 21.90 USD | -0.65 | -0.28 | 7.1M | On |
| 11 Sep 2026 | 15.50 USD | -7.3% | 14.57 USD | 22.05 USD | -0.69 | 2.25 | 3.4M | On |
| 4 Sep 2026 | 16.72 USD | -1.0% | 14.43 USD | 22.21 USD | -0.49 | 9.27 | 3.3M | On |
| 28 Aug 2026 | 16.89 USD | 0.9% | 14.25 USD | 22.35 USD | -0.30 | 10.31 | 2.7M | On |
| 21 Aug 2026 | 16.74 USD | -8.7% | 14.05 USD | 22.51 USD | 0.04 | 9.49 | 2.9M | On |
| 14 Aug 2026 | 18.34 USD | 6.3% | 13.89 USD | 22.67 USD | 0.46 | 16.79 | 3.0M | On |
| 7 Aug 2026 | 17.25 USD | 3.6% | 13.70 USD | 22.83 USD | 0.80 | 11.11 | 3.8M | On |
| 31 Jul 2026 | 16.65 USD | -15.9% | 13.57 USD | 23.00 USD | 1.09 | 12.83 | 7.4M | On |
| 24 Jul 2026 | 19.79 USD | 2.8% | 13.42 USD | 23.18 USD | 1.20 | 35.07 | 3.8M | On |
| 17 Jul 2026 | 19.25 USD | 2.4% | 13.18 USD | 23.34 USD | 1.28 | 29.95 | 4.9M | On |
| 10 Jul 2026 | 18.79 USD | 4.1% | 12.96 USD | 23.51 USD | 1.29 | 22.43 | 4.6M | On |
| 3 Jul 2026 | 18.05 USD | -3.8% | 12.78 USD | 23.66 USD | 1.29 | 20.08 | 3.4M | On |
| 26 Jun 2026 | 18.76 USD | 6.7% | 12.62 USD | 23.81 USD | 1.34 | 25.99 | 5.4M | On |
| 19 Jun 2026 | 17.58 USD | -1.1% | 12.43 USD | 23.95 USD | 1.30 | 13.17 | 4.9M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.